Drug Candidate Marketplace

Drug Candidate Marketplace lists the information of drug candidates, therapeutic targets and drug discovery technologies. Visitors can use search functions based on the interests and needs and download the list. If you have a drug candidates, therapeutic targets and drug discovery technologies that you are interested in and would like to gain more information, please contact us by clicking the inquiry button. Additional information will be provided to you.

Asset List(PDF) Asset List by Disease Area(PDF) Asset List(Excel)

Date Candidate Mechanism of action Indication Route Modality Development stage Note
10/12/21 GEM256 Stem cell repairing Osteoarthritis Intraーarticular Peptide Preclinical Synthetic novel PEDF-derived short peptide that stimulates cartilage regeneration morphology and pain relief efficacy (MIA-induced model, medial meniscal transection (MMT) model).
Long patent protection.Available for licensing globally.
Contact
10/12/21 GEM255 Stem cell repairing Neurotropic keratitis Topical (eye drop) Peptide Phase 1 Synthetic novel neurotrophic PEDF-derived short peptide that stimulates wound healing and corneal repair. Effectively regenerate healthy limbus after extensive limbal layer removal (Rabbit Model)
Long patent protection.Available for licensing globally.
Contact
10/12/21 GEM254 Stem cell repairing Dry eye syndrome Topical (eye drop) Peptide Phase 2 Synthetic PEDF-derived short peptide to stimulate proliferation and differentiation of corneal limbal stem cells to speed up cornea repair process. Repair severe cornea damages for patients
lacking treatment options.
The Phase 2 studies demonstrated that GEM254 is safe, effective, and the results are reproducible.
Long patent protection.
Available for licensing globally excluding China.
Contact
09/17/21 GEM253 Influenza Virus-Neutralizing antibody Influenza i.v. Antibody Preclinical Neutralizing activity against Influenza virus, human H1N1, H2N2, H3N2, H5N1, and avian H3N8.
Passive immunization with the pan-neutralizing antibody enables to effectively prevent or treat influenza even in the event of an antigenic shift, as well as an antigenic drift.
Contact
09/14/21 GEM252 Cultured skin stem cells autografts Spinal cord injury Trans-plant into spinal cord (Auto-logus) Cell therapy Clinical application finished The Skin stem cells cultured in serum-free medium express Nestin, CD73, and GDNF. They showed no tumorigenicity in carcinogenicity test. Autologous transplantation for patients with spinal cord injury was performed with intraspinal administration via lumbar puncture. A most aggressive result was a case which a man with 2.5years paralysis of lower limbs by Th3 site injury, who recovered to the level of walking after receiving 2 times. Contact
09/08/21 GEM251 Antisense oligo nucleotide (ASO) suppressing the expression of human p53 gene AKI(acute kidney injury), Heart failure, Stroke i.v. Nucleic acid Discovery/ Preclinical Same as GEM248 Contact
09/08/21 GEM250 Antisense oligo nucleotide (ASO) suppressing the expression of human p53 gene Drug-induced alopecia Topical Nucleic acid Discovery Same as GEM248 Contact
09/08/21 GEM249 Antisense oligo nucleotide (ASO) suppressing the expression of human p53 gene Sensorineural Hearing Loss Topical Nucleic acid Discovery Same as GEM248 Contact
09/08/21 GEM248 Antisense oligo nucleotide (ASO) suppressing the expression of human p53 gene ALS(C9orf72) Intraーmedullary Nucleic acid Discovery Suppression of p53 expression may reduce the tissue damage and enhance tissue repair in several disease conditions. It inhibits p53 expression better than the competitor compound in cultured cell, and is therefore expected to be highly effective in clinical practice. Contact
08/25/21 GEM247 Activation of progenitor and endothelial progenitor cells Chronic limb threatening ischemia Injection and device Regenerative therapy Clinical Regenerative therapy for vascular disease promotes new vessel growth. Excellent clinical results include pain relief, wound healing, hemodynamic improvement, new collaterals visible on angiography, biochemical support for mechanism of action, and limb salvage. Contact